ABCDEFGHI
1
CLINICAL TRIALS
2
Epithelial Ovarian Cancer
3
Source: clinicaltrials.gov
4
5
ICAN advises every patient and other interested person, after reviewing this clinical trials spreadsheet, to check out clinical trials directly at www.cancer.gov in case there are updates since the date of this posting. ICAN does not purport to provide medical advice or to indicate which trial is suitable for a certain patient. Please consult your medical oncology team and the principal investigator in charge of the trial in which you are interested for information most relevant to your specific medical situation and decision-making process.Contact Information
6
No.LinkTitleOfficial TitlePurposeCitationOrganization/SponsorCollaboratorStatus
7
8
1http://clinicaltrials.gov/ct2/show/NCT00483782Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian CancerThis randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab to see how well they work compared with carboplatin and paclitaxel alone in treating patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.http://clinicaltrials.gov/ct2/show/NCT00483782 - Retrieved June 2012Medical Research CouncilCurrently recruiting
9
2http://clinicaltrials.gov/ct2/show/NCT00993655Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerA Phase II/III Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous ChemotherapyThis randomized phase II/III trial is comparing the side effects of three combination chemotherapy regimens and to see how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.http://clinicaltrials.gov/ct2/show/NCT00993655 - Retrieved June 2012NCIC Clinical Trials GroupNational Cancer Institute (NCI); Grupo Espanol de Investigacion en Cancer de Ovario; Cancer Research UK; Southwestern Oncology Group (SWOG)Currently recruiting
10
3http://clinicaltrials.gov/ct2/show/NCT00562640Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)A Phase I Dose Escalation Safety and Feasibility Study of WT1-Specific T Cells for the Treatment of Patients With Advanced Ovarian, Primary Peritoneal, and Fallopian Tube CarcinomasThis phase I trial is studying the side effects and best dose of autologous T cells when given with or without cyclophosphamide and fludarabine in treating patients with recurrent or persistent advanced ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. (fludarabine treatment closed as of 12/012009)http://clinicaltrials.gov/ct2/show/NCT00562640 - Retrieved June 2012Memorial Sloan-Kettering Cancer CenterNational Cancer Institute (NCI) Currently recruiting
11
4http://clinicaltrials.gov/ct2/show/NCT01439490FES-PET to Determine ER-expression in Epithelial Ovarian CancerFeasibility Study: FES-PET to Determine ER-expression in Epithelial Ovarian CancerEstrogens are implicated in the development of ovarian cancer and estrogen receptors (ER) alpha and beta are present in 20-100% of ovarian cancer patients. For this reason, antihormonal therapy with anti-estrogens or ER-antagonists is potentially an attractive treatment option. However, only a small proportion of patients (5-19%) will respond to antihormonal therapy. ER-expression in ER-positive breast cancer can be assessed by positron emission tomography (PET) with 18F-fluoroestradiol (FES). In this study the investigators will evaluate whether FES-PET can be used to visualize and quantify ER-expression in ovarian cancer. If these results are positive, this would warrant further exploration of FES-PET imaging in ovarian cancer.http://clinicaltrials.gov/ct2/show/NCT01439490 - Retrieved June 2012University Medical Centre GroningenCurrently recruiting
12
5http://clinicaltrials.gov/ct2/show/NCT01276574Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT (Mupet)Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT(Positron Emission Tomography/Computed Tomography)Refer to clinical trials website.http://clinicaltrials.gov/ct2/show/NCT01276574 - Retrieved June 2012Turku University HospitalCurrently recruiting
13
6http://clinicaltrials.gov/ct2/show/NCT01481701A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian CarcinomaA Non Randomized Stratified Phase II Trial Evaluating Efficacy and Safety of Oxaliplatin in Combination With 5-Fluorouracil in Patients With Platinum-sensitive and Platinum-resistant Recurrent Ovarian CarcinomaThis is a Phase II study for recurrent ovarian carcinoma platinum-sensitive and resistant tumors Folfox regimen.http://clinicaltrials.gov/ct2/show/NCT01481701 - Retrieved June 2012Jules Bordet InstituteCurrently recruiting
14
7http://clinicaltrials.gov/ct2/show/NCT01081262Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube CancerA GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #7921) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian Cancer or Fallopian Tube Cancer (MEOC)This randomized phase III trial is studying carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as first-line therapy in treating patients with newly diagnosed stage II, stage III, stage IV, or recurrent stage I epithelial ovarian cancer or fallopian tube cancer.http://clinicaltrials.gov/ct2/show/NCT01081262 - Retrieved June 2012University College, LondonNational Cancer Institute (NIC); Gynecologic Oncology GroupCurrently recruiting
15
8http://clinicaltrials.gov/ct2/show/NCT00857545OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete RemissionA Phase II Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLH Conjugate (NSC 748933) + OPT-821 Versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in Second or Third Complete RemissionThis randomized phase III trial is studying OPT-821 and vaccine therapy to see how well they work compared with OPT-821 alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission.http://clinicaltrials.gov/ct2/show/NCT00857545 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
16
9http://clinicaltrials.gov/ct2/show/NCT00004876Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial CancerA Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian CancerThis randomized phase II trial is studying how well giving carboplatin together with thalidomide works compared to carboplatin alone in treating patients with ovarian epithelial cancer.http://clinicaltrials.gov/ct2/show/NCT00004876 - Retrieved June 2012Cancer Research UKCurrently recruiting
17
10http://clinicaltrials.gov/ct2/show/NCT00850772Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer (OPEN)Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian CancerRefer to clinical trials website.http://clinicaltrials.gov/ct2/show/NCT00850772 - Retrieved June 2012Queensland Centre for Gynaecological CancerCancer Australia; The University of QueenslandCurrently recruiting
18
11http://clinicaltrials.gov/ct2/show/NCT00647062AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated, Hereditary, or Triple Negative Metastatic or Unresectable Breast Cancer or Ovarian Epithelial CancerA Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers (Familial Breast and Ovarian Cancer) and Sporadic Triple Negative Breast Cancer and Ovarian CancerThis phase I trial is studying the side effects and best dose of AZD2281 when given together with carboplatin in treating patients with BRCA1/BRCA2-associated, hereditary, or triple negative metastatic or unresectable breast cancer or ovarian epithelial cancer.http://clinicaltrials.gov/ct2/show/NCT00647062 - Retrieved June 2012National Cancer Institute (NCI)Currently recruiting
19
12http://clinicaltrials.gov/ct2/show/NCT01391351Search for Predictors of Therapeutic Response in Ovarian Carcinoma (miRSa)Search for Predictors of Therapeutic Response in Patients With Carcinoma of the Ovary, the Fallopian Tube or Peritoneal Serous-type Advancedorder to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months).http://clinicaltrials.gov/ct2/show/NCT01391351 - Retrieved June 2012Centre Francois BaclesseCurrently recruiting
20
13http://clinicaltrials.gov/ct2/show/NCT00628654Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female ParticipantsClinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian CancerThis clinical trial is studying how well glycan analysis works in diagnosing cancer in women with ovarian epithelial cancer and in healthy female participants.http://clinicaltrials.gov/ct2/show/NCT00628654 - Retrieved June 2012University of California, DavisNational Cancer Institute (NCI)Currently recruiting
21
14http://clinicaltrials.gov/ct2/show/NCT00899093Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing ChemotherapyA Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary ChemotherapyThis laboratory study is assessing tumor marker YKL-40 in patients with newly diagnosed stage III or stage IV ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer undergoing chemotherapyhttp://clinicaltrials.gov/ct2/show/NCT00899093 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
22
15http://clinicaltrials.gov/ct2/show/NCT01010126Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid TumorA Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell CancerThis phase II trial is studying the side effects of giving temsirolimus together with bevacizumab and to see how well it works in treating patients with locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor.http://clinicaltrials.gov/ct2/show/NCT01010126 - Retrieved June 2012Mayo ClinicNational Cancer Institute (NCI)Currently recruiting
23
16http://clinicaltrials.gov/ct2/show/NCT00989651Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerA Phase I Study of Carboplatin/Paclitaxel/CTEP Supplied Agent Bevacizumab (NSC #704865, IND #7921) and CTEP Supplied Agent ABT-888 (NSC #737664 IND#77840) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerThis phase I trial is studying the side effects and best dose of ABT-888 when given together with carboplatin, paclitaxel, and bevacizumab in treating patients with newly diagnosed stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancerhttp://clinicaltrials.gov/ct2/show/NCT00989651 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
24
17http://clinicaltrials.gov/ct2/show/NCT01175967Changes in Performance Status and Symptom Distress in Older Patients With Advanced Ovarian Epithelial Cancer Undergoing Surgery and/or ChemotherapyUse of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian CancerThis clinical trial is studying changes in performance status and symptoms distress in older patients with advanced ovarian epithelial cancer undergoing surgery and/or chemotherapy.http://clinicaltrials.gov/ct2/show/NCT01175967 - Retrieved June 2012UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)Currently recruiting
25
18http://clinicaltrials.gov/ct2/show/NCT00886691Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerA Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerThis randomized phase II trial is studying bevacizumab to see how well it works when given with or without everolimus in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT00886691 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
26
19http://clinicaltrials.gov/ct2/show/NCT00565851Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube CancerA Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube CancerThis randomized phase III trial is studying giving carboplatin and paclitaxel together with or without bevacizumab after surgery to see how well it works in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer.http://clinicaltrials.gov/ct2/show/NCT00565851 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
27
20http://clinicaltrials.gov/ct2/show/NCT01118052EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerA Phase II Evaluation of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerThis phase II clinical trial is studying the side effects and how well EGEN-001 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01118052 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
28
21http://clinicaltrials.gov/ct2/show/NCT01039207AMG 102 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerA Phase II Evaluation of AMG 102 (IND # 107579, NSC #750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaThis phase II trial is studying how well AMG 102 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01039207 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
29
22http://clinicaltrials.gov/ct2/show/NCT00602277Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum ChemotherapyA Phase 1 Study of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) (NSC 729968) in Patients With Ovarian, Primary Peritoneal and Fallopian Tube CarcinomaThis phase I/II trial is studying the side effects and best dose of viral therapy in treating patients with ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that did not respond to platinum chemotherapy phase II closed as of 1/7/2011)..http://clinicaltrials.gov/ct2/show/NCT00602277 - Retrieved June 2012Arthur G. James Cancer Hospital & Richard J. Solove Research InstituteNational Cancer Institute (NCI)Currently recruiting
30
23http://clinicaltrials.gov/ct2/show/NCT00408590Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal CancerPhase I Trial of Intraperitoneal Administration of a) a CEA-Expressing Derivative, and b) a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian CancerThis phase I trial is studying the side effects and best dose of an attenuated oncolytic measles virus therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer (measles virus vaccine therapy study closed as of 06/02/2008).http://clinicaltrials.gov/ct2/show/NCT00408590 - Retrieved June 2012Mayo ClinicNational Cancer Institute (NCI)Currently recruiting
31
24http://clinicaltrials.gov/ct2/show/NCT01100372Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerRandomized Phase II AGO-Study Comparing Combined Liposomal Doxorubicin (Myocet) and Gemcitabine (Gemzar) With Liposomal Doxorubicin (Myocet) Monotherapy in Platinum-Refractory and Platinum-Resistant Epithelial Cancer of the Ovary, Fallopian Tube and the PeritoneumThis randomized phase II trial is studying liposome-encapsulated doxorubicin citrate given together with gemcitabine hydrochloride to see how well it works compared with liposome-encapsulated doxorubicin citrate alone in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancerhttp://clinicaltrials.gov/ct2/show/NCT01100372 - Retrieved June 2012Innsbruck UniversitaetsklinikCurrently recruiting
32
25http://clinicaltrials.gov/ct2/show/NCT01074411Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerA Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240) in Patients With Persistent or Recurrent, Ovarian, Fallopian Tube, or Primary Peritoneal CancerThis phase I trial is studying the side effects and best dose of intraperitoneal bortezomib when given together with intraperitoneal carboplatin in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01074411 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
33
26http://clinicaltrials.gov/ct2/show/NCT01402271Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerPhase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal CarcinomaThis randomized phase I/II trial is studying the side effects and best dose of pazopanib hydrochloride when given together with paclitaxel and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01402271 - Retrieved June 2012European Organization for Research and Treatment of Cancer - EORTCNot yet recruiting
34
27http://clinicaltrials.gov/ct2/show/NCT01012817ABT-888 and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Ovarian Epithelial Cancer or Primary Peritoneal CancerA Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line ChemotherapyThis phase I/II trial is studying the side effects and best dose of giving ABT-888 together with topotecan hydrochloride and to see how well it works in treating patients with advanced solid tumors or relapsed or refractory ovarian epithelial cancer or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01012817 - Retrieved June 2012Mayo ClinicNational Cancer Institute (NCI)Currently recruiting
35
28http://clinicaltrials.gov/ct2/show/NCT01492920Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing ChemotherapyA Randomized, Double-Blind, Placebo Controlled Phase III Trial Using ACETYL-L-Carnitine (ALC) (NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerThis randomized phase III trial studies how well acetyl-L-carnitine hydrochloride works compared to a placebo in preventing peripheral neuropathy in patients with recurrent ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer undergoing chemotherapy.http://clinicaltrials.gov/ct2/show/NCT01492920 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruiting
36
29http://clinicaltrials.gov/ct2/show/NCT01489371EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerA Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With Pegylated Liposomal Doxorubicin (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerThis phase I trial studies the side effects and the best dose of giving EGEN-001 together with pegylated liposomal doxorubicin hydrochloride in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01489371 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruiting
37
30http://clinicaltrials.gov/ct2/show/NCT01536743A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 ExpressionA Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 ExpressionThe purpose of this study is to obtain an estimate of the biochemical response rate as determined by CA125 response using the Gynecologic Cancer Intergroup (GCIG) response criteria of PD0332991 in patients with recurrent ovarian epithelial carcinoma. CA125 response is defined as ≥ 50% decrease from the baseline CA125 level and confirmed ≥ 21 days after initial evaluation (baseline is defined as the higher value of 2 pre-treatment CA125 assessments).http://clinicaltrials.gov/ct2/show/NCT01536743 - Retrieved June 2012Jonsson Comprehensive Cancer CenterCurrently recruiting
38
31http://clinicaltrials.gov/ct2/show/NCT01164995Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat Ovarian Cancer (M10MKO)Phase II Pharmacological Study With Wee-1 Inhibitor MK-1775 Combined With Carboplatin in Patients With p53 Mutated Epithelial Ovarian Cancer and Early Relapse (< 3 Months) or Progression During Standard First Line TreatmentThe purpose of this study is to determine if patients with p53 mutated epithelial ovarian cancer that have been treated with first line treatment (paclitaxel - carboplatin combination therapy) and that have shown early relapse (within 3 months) or progression during treatment will benefit from treatment with Wee-1 inhibitor MK-1775 and carboplatin.http://clinicaltrials.gov/ct2/show/NCT01164995 - Retrieved June 2012The Netherlands Cancer InstituteMerckCurrently recruiting
39
32http://clinicaltrials.gov/ct2/show/NCT01175343RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerPhase II Study of RO4929097 (IND 105994) in Advanced Platinum Resistant Ovarian CancerThis phase II trial is studying the side effects and how well RO4929097 works in treating patients with recurrent and/or metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01175343 - Retrieved June 2012University Health Network, TorontoNational Cancer Institute (NCI)Currently recruiting
40
33http://clinicaltrials.gov/ct2/show/NCT01536054Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerA Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal CancerThis phase I trial studies the side effects and best dose and schedule of sirolimus when given together with vaccine therapy in treating patients with stage II-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy together with sirolimus may be an effective treatment for ovarian, fallopian tube, or primary peritoneal cancerhttp://clinicaltrials.gov/ct2/show/NCT01536054 - Retrieved June 2012Roswell Park Cancer InstituteNational Cancer Institute (NCI)Not yet recruiting
41
34http://clinicaltrials.gov/ct2/show/NCT01175772Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment StrategyMaintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy With Metronomic/Oral Chemotherapy (Cytophosphan Combined With Low-dose Methotrexate)and COX-2 Inhibition (Celecoxib)Refer to clinical trials website.http://clinicaltrials.gov/ct2/show/NCT01175772 - Retrieved June 2012HaEmek Medical Center, IsraelCurrently recruiting
42
35http://clinicaltrials.gov/ct2/show/NCT01522820Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsA Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-Tumor Immunity In Patients With NY-ESO-1 Expressing Solid TumorsThis phase I trial studies the side effects and best schedule of vaccine therapy when given together with or without sirolimus in treating patients with NY-ESO-1 expressing solid tumors. Biological therapies, such as sirolimus, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. Is not yet known whether vaccine therapy is more effective when given with or without sirolimus in treating solid tumorshttp://clinicaltrials.gov/ct2/show/NCT01522820 - Retrieved June 2012Roswell Park Cancer InstituteCurrently recruiting
43
36http://clinicaltrials.gov/ct2/show/NCT01456065Safety of Active Immunotherapy in Subjects With Ovarian CancerA Phase I, Open, Randomized, Study to Investigate the Safety of Active Immunotherapy With Fully Mature, TERT-mRNA and Survivin - Peptide Double Loaded Dentritic Cells (DCs) in Subjects With Advanced Epithelial Ovarian Cancer, Enrolled in the Study Within Twelve Weeks After Completing Primary TherapyThe purpose of this study is to investigate the safety of the active immune therapy based on the reiterated injection of fully mature, TERT (Telomerase Reverse Transcriptase)-mRNA and Survivin-peptide double loaded DCs (Dendritic Cells) [Procure®] in patients with advanced ovarian cancer, enrolled into the study within twelve weeks after completing primary therapy.http://clinicaltrials.gov/ct2/show/NCT01456065 - Retrieved June 2012Life Research Technologies GmbHCurrently recruiting
44
37http://clinicaltrials.gov/ct2/show/NCT01196429Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian CancerA Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864, IND# 61010) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the OvaryThis phase II trial is studying how well giving temsirolimus, carboplatin, and paclitaxel together as first-line therapy works in treating patients with newly diagnosed stage III or stage IV clear cell ovarian cancer.http://clinicaltrials.gov/ct2/show/NCT01196429 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
45
38http://clinicaltrials.gov/ct2/show/NCT01494012Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian CancerA Phase I Study Evaluating the Efficacy and Toxicity of Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian CancerThis phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.http://clinicaltrials.gov/ct2/show/NCT01494012 - Retrieved June 2012Stanford UniversityCurrently recruiting
46
39http://clinicaltrials.gov/ct2/show/NCT01322802Vaccine Therapy in Treating Patients With Stage III-IV Ovarian CancerA Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian CancerThis phase I trial is studying the side effects of vaccine therapy in treating patients with stage III-IV ovarian cancer. Vaccines made from DNA may help the body build an effective immune response to kill tumor cellshttp://clinicaltrials.gov/ct2/show/NCT01322802 - Retrieved June 2012Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumNational Cancer Institute (NCI)Currently recruiting
47
40http://clinicaltrials.gov/ct2/show/NCT01511055Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent LigandPhase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent LigandRefer to clinical trials website.http://clinicaltrials.gov/ct2/show/NCT01511055 - Retrieved June 2012Mayo ClinicCurrently recruiting
48
41http://clinicaltrials.gov/ct2/show/NCT01095367Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian CancerSeprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian CancerRefer to clinical trials website.http://clinicaltrials.gov/ct2/show/NCT01095367 - Retrieved June 2012University of British ColumbiaGenzymeCurrently recruiting
49
42http://clinicaltrials.gov/ct2/show/NCT01606358Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer (IClyCO)IClyCO Influence of Chemotherapy (Carboplatin and Taxol) on the ex Vivo Expansion and Functional Capacity of Gamma-delta T Cells in Patients With Epithelial Ovarian CancerRefer to clinical trials website.http://clinicaltrials.gov/ct2/show/NCT01606358 - Retrieved June 2012Rennes University HospitalCurrently recruiting
50
43http://clinicaltrials.gov/ct2/show/NCT01376752Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment (CHIPOR)A Phase III Randomized Study of Phase III Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian CancerCHIPOR hypothesis is that the adjunction of platinum HIPEC in first relapsed epithelial ovarian cancer is able to improve the median OS by 12 months. In that hypothesis, with alpha risk of 5%, a power beta of 80%, during a 3 years period of inclusion and a 3 years follow-up, the number of patients to include is 404. Taking into account a 10% failure, an overall number of 444 patients is required.http://clinicaltrials.gov/ct2/show/NCT01376752 - Retrieved June 2012UNICANCERCurrently recruiting
51
44http://clinicaltrials.gov/ct2/show/NCT00718523Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian CancerThis study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with optimally debulked (<1 cm) FIGO stage III and IV (positive pleural cytology only) ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.http://clinicaltrials.gov/ct2/show/NCT00718523 - Retrieved June 2012Cancer International Research GroupCurrently recruiting
52
45http://clinicaltrials.gov/ct2/show/NCT01121640A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk WomenRandomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk WomenThe Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can be used as a screening method for the early detection of epithelial ovarian cancer.http://clinicaltrials.gov/ct2/show/NCT01121640 - Retrieved June 2012Fred Hutchinson Cancer Research CenterRefer to clinical trial website.Currently recruiting
53
46http://clinicaltrials.gov/ct2/show/NCT00770536A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian CancerA Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian CancerThis study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer. Up to 100 subjects will be enrolled to receive AMG 386 in combination with either pegylated liposomal doxorubicin every 4 weeks (cohort A) or topotecan weekly on days 1, 8, and 15 of a 28 day dosing schedule (cohort B). Subject enrollment and assignment to either cohort will be based on eligibility and the investigator's discretion.http://clinicaltrials.gov/ct2/show/NCT00770536 - Retrieved June 2012AmgenCurrently recruiting
54
47http://clinicaltrials.gov/ct2/show/NCT01549925Surgical Trial Comparing LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to StandProspective Randomized Surgical Trial Comparing the Efficacy of LIGASURE Assisted Recto-Sigmoid Resection and Omentectomy Compared to Standard Surgical Resection in Women With Stage IIIC or Stage IVA Epithelial Ovarian CancerThe objective of this prospective randomized surgical trial is to evaluate whether the use of the LIGASURE surgical device during omentectomy and/or recto-sigmoid resection for women with ovarian cancer will reduce the surgical time compared to standard surgical resection using clamps and surgical ligatures.http://clinicaltrials.gov/ct2/show/NCT01549925 - Retrieved June 2012University of UtahCurrently recruiting
55
48http://clinicaltrials.gov/ct2/show/NCT01472783Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation (Veli-BRCA)Veliparib (ABT888) Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian CancerThe main purpose of this study is to investigate the effect of veliparib in ovarian cancer patients with known BRCA 1/2 mutations who do no longer respond to conventional chemotherapy.http://clinicaltrials.gov/ct2/show/NCT01472783 - Retrieved June 2012Vejle HospitalAbbottCurrently recruiting
56
49http://clinicaltrials.gov/ct2/show/NCT01177501Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma (ITOV04)Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 MonthsThe early relapse of ovarian cancer occurring within 6 months of chemotherapy including platinum regimen are called relapses 'platinum resistant' consecutively patients die quickly of their disease. For relapses occurring between 6 and 12 months, no recommendation occur and few studies are conducted. Therefore it seems interesting to develop a research on intensive chemotherapy using a combination of carboplatin (a drug widely used in most ovarian cancer) with Topotecan , use in a high dose protocol. Topotecan has demonstrated its efficacy in relapse ovarian cancer and its possible use in high doses, a recent study (ITOV01) have demonstrated the feasibility of dose escalation of topotecan monotherapy (MTD set at 9 mg / m² / dx 5 days). This project is a feasibility research of the combination of topotecan and carboplatin in a high dose escalation protocol for early ovarian cancer relapse occurring 6 to 12 months after conventional chemotherapy-based platinum salts.http://clinicaltrials.gov/ct2/show/NCT01177501 - Retrieved June 2012Assistance Publique - Hôpitaux de ParisCurrently recruiting
57
50http://clinicaltrials.gov/ct2/show/NCT00889382A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)A Phase 1/2 Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.http://clinicaltrials.gov/ct2/show/NCT00889382 - Retrieved June 2012Astellas Pharma IncCurrently recruiting
58
51http://clinicaltrials.gov/ct2/show/NCT01281514Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerPHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSEThis phase I trial is studying the side effects and best dose of everolimus when given together with carboplatin and PLD in treating patients with relapsed ovarian epithelial, fallopian tube, or peritoneal cavity cancerhttp://clinicaltrials.gov/ct2/show/NCT01281514 - Retrieved June 2012Fox Chase Cancer CenterNational Cancer Institute (NCI)Currently recruiting
59
52http://clinicaltrials.gov/ct2/show/NCT01506856Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (iPocc)A RANDOMIZED PHASE II/ III TRIAL OF INTRAVENOUS (IV) PACLITAXEL WEEKLY PLUS IV CARBOPLATIN ONCE EVERY 3 WEEKS VERSUS IV PACLITAXEL WEEKLY PLUS INTRAPERITONEAL (IP) CARBOPLATIN ONCE EVERY 3 WEEKS IN WOMEN WITH EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCERThe purpose of this study is: Phase A: To confirm the feasability of paclitaxel administered by intravenous (IV) infusion weekly plus concurrent carboplatin administered by intraperitoneal (IP) injection once every 3 weeks (dd-TCip therapy); Phase B: To compare the efficacy and safety of the following two treatment regimens as first-line chemotherapy in women with epithelial ovarian, Fallopian tube or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01506856 - Retrieved June 2012Gynecologic Oncology Trial & Investigation ConsortiumJapanese Gynecologic Oncology GroupCurrently recruiting
60
53http://clinicaltrials.gov/ct2/show/NCT01484015Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaProlonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot StudyThis randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochloride over the standard time.http://clinicaltrials.gov/ct2/show/NCT01484015 - Retrieved June 2012Comprehensive Cancer Center of Wake Forest UniversityNational Cancer Institute (NCI)Currently recruiting
61
54http://clinicaltrials.gov/ct2/show/NCT01295489Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal CancerA Limited Institution Study of the Local and Systemic Effects of Intraperitoneal Chemotherapy in the Treatment of Previously-Untreated, Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal CarcinomaThis research study is studying biomarkers in patients with previously untreated invasive ovarian epithelial, fallopian tube, or peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01295489 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
62
55http://clinicaltrials.gov/ct2/show/NCT00968799Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility StudyHyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility StudyRefer to clinical trials website.http://clinicaltrials.gov/ct2/show/NCT00968799 - Retrieved June 2012Cantonal Hospital of St. GallenCurrently recruiting
63
56http://clinicaltrials.gov/ct2/show/NCT01366183Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerChemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube CancerThis trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.http://clinicaltrials.gov/ct2/show/NCT01366183 - Retrieved June 2012Gynecologic Oncology GroupCurrently recruiting
64
57http://clinicaltrials.gov/ct2/show/NCT01442051Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian CancerA Pilot Study of Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian CancerRefer to clinical trials website.http://clinicaltrials.gov/ct2/show/NCT01442051 - Retrieved June 2012Memorial Sloan-Kettering Cancer CenterCurrently recruiting
65
58http://clinicaltrials.gov/ct2/show/NCT01308944Therapeutic Targeting of Stress Factors in Ovarian Cancer PatientsFeasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer PatientsThis research is looking at the effect of biobehavioral factors such as stress and whether these factors alter how the body responds to chemotherapy, one of the purposes of this study is to determine if the addition of a beta-blocker such as Propranolol (Inderal) is tolerable when given with chemotherapy in the treatment of newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer. An additional purpose of the study is to understand if behavioral factors such as depression and anxiety can alter different blood markers that affect tumor vascularity. The Investigator wishes to determine whether the use of beta-blocker drugs such as Inderal, might alter these behavioral factors by drawing blood prior to and after the administration of Inderal as well as giving behavioral questionaires at different time points. Beta-blockers are commonly used for the treatment of hypertension, protection of the heart after a heart attack, and irregularities in heartbeats. Altering these factors might boost the immune system and affect other areas of cancer biology, thereby allowing the chemotherapy to be more effective. The significance of this research is that it may help improve our treatments of this disease in the future.http://clinicaltrials.gov/ct2/show/NCT01308944 - Retrieved June 2012Washington University School of MedicineCurrently recruiting
66
59http://clinicaltrials.gov/ct2/show/NCT00986206Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian CancerDevelopment of an Assay for the Early Detection of Ovarian Cancer.This clinical trial is studying using the lysophosphatidic acid assay to see how well it works in early detection of ovarian cancer in patients with ovarian cancer or who are at risk for ovarian cancer.http://clinicaltrials.gov/ct2/show/NCT00986206 - Retrieved June 2012Women and Infants Hospital of Rhode IslandNational Cancer Institute (NCI)Currently recruiting
67
60http://clinicaltrials.gov/ct2/show/NCT01080521Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving ChemotherapyA Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube CancerThis clinical trial is studying changes in brain function in patients with stage I, stage II, stage III, or stage IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy.http://clinicaltrials.gov/ct2/show/NCT01080521 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
68
61http://clinicaltrials.gov/ct2/show/NCT00954174Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian CancerA Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or OvaryThis randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works compared with giving paclitaxel together with ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine or ovarian cancer.http://clinicaltrials.gov/ct2/show/NCT00954174 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
69
62http://clinicaltrials.gov/ct2/show/NCT01372787Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal CancerQuality of Life and Care Needs in Patients With Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube, and Peritoneal CancerThis clinical trial studies the quality of life and care needs of patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01372787 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
70
63http://clinicaltrials.gov/ct2/show/NCT01146795Neoadjuvant Therapy for Ovarian CancerFeasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal CancerThis study is to determine the feasibility of administering neoadjuvant carboplatin, paclitaxel, and bevacizumab without excessive dose modification or cycle delay in patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.http://clinicaltrials.gov/ct2/show/NCT01146795 - Retrieved June 2012Columbia UniversityGenentechCurrently recruiting
71
64http://clinicaltrials.gov/ct2/show/NCT00664781Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian CancerA Cancer Research UK Phase II Proof of Principle Trial of the Activity of the PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian CancerThis phase II trial is studying the side effects and best dose of rucaparib and to see how well it works in treating patients with locally advanced or metastatic breast cancer or advanced ovarian cancer.http://clinicaltrials.gov/ct2/show/NCT00664781 - Retrieved June 2012Cancer Research UKCurrently recruiting
72
65http://clinicaltrials.gov/ct2/show/NCT01131234Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsA Phase 1, Pharmacokinetic and Pharmacodynamic Study of the Combination of RO4929097 and Cediranib in Patients With Advanced Solid TumorsThis phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors.http://clinicaltrials.gov/ct2/show/NCT01131234 - Retrieved June 2012Princess Margaret Hospital, CanadaNational Cancer Institute (NCI)Currently recruiting
73
66http://clinicaltrials.gov/ct2/show/NCT00946283Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic SyndromeProbiotic Enteric Regimen For Easing Complications of Transplant : A Pilot Study (PERFECT Trial)This phase I trial is studying the side effects and how well giving enteral nutrition, including Lactobacillus, works in preventing infections in patients undergoing donor stem cell transplant for hematologic cancer or myelodysplastic syndrome.http://clinicaltrials.gov/ct2/show/NCT00946283 - Retrieved June 2012University of Medicine and Dentistry New JerseyNational Cancer Institute (NCI)Currently recruiting
74
67http://clinicaltrials.gov/ct2/show/NCT01172028Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid TumorsPhase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor PatientsThis phase I trial is studying the side effects and best dose of giving pemetrexed disodium and docetaxel together in treating patients with advanced solid tumors.http://clinicaltrials.gov/ct2/show/NCT01172028 - Retrieved June 2012University of ArizonaNational Cancer Institute (NCI)Currently recruiting
75
68http://clinicaltrials.gov/ct2/show/NCT00108745Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube CancerA Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane ChemotherapyThis randomized phase III trial is studying paclitaxel to see how well it works compared to polyglutamate paclitaxel or observation only in treating patients with stage III or stage IV ovarian epithelial or peritoneal cancer or fallopian tube cancer.http://clinicaltrials.gov/ct2/show/NCT00108745 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
76
69http://clinicaltrials.gov/ct2/show/NCT01334047Trial of Vaccine Therapy in Recurrent Platinum Resistant Ovarian Cancer PatientsPhase I/II Trial of Vaccine Therapy in Recurrent Platinum Resistant Ovarian Cancer Patients Using Autologous Dendritic Cells Loaded With Amplified Ovarian Cancer Stem Cell mRNA, hTERT and SurvivinIn this study the investigators will include patients with relapsed and platinum resistant epithelial ovarian cancer. They have an unfavorable prognosis and there is currently no treatment able to extend survival. Currently, relapsed platinum resistant patients are treated with a variety of chemotherapy drugs to reduce symptoms of disease. In this study, patients are included after receiving no more than one line of chemotherapy treatment in resistant disease. The investigators include patients in good clinical condition with no severe symptoms of the disease. If the patients develop symptoms that can be treated with chemotherapy, they will be discontinued from the study.
The investigators have included hTERT- and survivin mRNA in addition to amplified cancer stem cell mRNA in the vaccine.		http://clinicaltrials.gov/ct2/show/NCT01334047 - Retrieved June 2012Oslo University HospitalCurrently recruiting
77
70http://clinicaltrials.gov/ct2/show/NCT01249443Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionA Phase I Study of Vorinostat in Combination With Paclitaxel and Carboplatin in Solid Tumors (With Focus on Upper Aerodigestive Cancers) in Persons With HIV InfectionThis phase I clinical trial is studying the side effects and the best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with metastatic or recurrent solid tumors and HIV infection.http://clinicaltrials.gov/ct2/show/NCT01249443 - Retrieved June 2012AIDS Associated Malignancies Clinical Trials ConsortiumNational Cancer Institute (NCI)Currently recruiting
78
71http://clinicaltrials.gov/ct2/show/NCT00825201Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal CavityPhase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal CavityThis phase I trial is studying the side effects and best dose of intraperitoneal paclitaxel albumin-stabilized nanoparticle formulation in treating patients with advanced cancer of the peritoneal cavity.http://clinicaltrials.gov/ct2/show/NCT00825201 - Retrieved June 2012City of Hope Medical CenterNational Cancer Institute (NCI) ; National Comprehensive Cancer NetworkCurrently recruiting
79
72http://clinicaltrials.gov/ct2/show/NCT01239732A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerGlobal Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal CarcinomaThis open-label, non-comparative, multi-center study will assess the safety profile and efficacy of Avastin (bevacizumab) when added to carboplatin and paclitaxel therapy in patients with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma. Patients will receive 15 mg/kg Avastin intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each, carboplatin (AUC 5-6 mg/ml/min) on Day 1 every 3 weeks for a maximum of 8 cycles and paclitaxel 175 mg/m2 on Day 1 every 3 weeks or 80 mg/m2 every week for a maximum of 8 cycles. The anticipated time on study drug will be 108 weeks or until disease progression or unacceptable toxicity.http://clinicaltrials.gov/ct2/show/NCT01239732 - Retrieved June 2012Hoffmann-La RocheCurrently recruiting
80
73http://clinicaltrials.gov/ct2/show/NCT01309230Trial of Adjuvant FANG™ Vaccine for High Risk Stage IIIc Ovarian Cancer (FANG Ovarian)Randomized Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage IIIc Ovarian CancerThis is a Phase II 2:1 randomized study of adjuvant intradermal autologous FANG™ cancer vaccine (1.0 x 10^7 cells/injection; maximum of 12 vaccinations) in women with stage IIIC epithelial ovarian cancer who attain a clinical or pathologic complete response (including a post-treatment, prevaccination baseline serum CA-125 level of ≤ 20 units/ml) after primary surgical cytoreduction and a total of six courses of front-line (pre- and post- or post-surgical) chemotherapy. The comparison arm will be standard of care observational follow-up. At recurrence, patients will be stratified into cisplatin-sensitive and -resistant groups and treated with second-line chemotherapy. The response rate and duration of response to second-line therapy in patients with or without prior FANG™ will be compared. Trial endpoints include time to recurrence (TTR), documentation of immune responses, and correlation of immune response and clinical effect.http://clinicaltrials.gov/ct2/show/NCT01309230 - Retrieved June 2012Gradalis, Inc.Currently recruiting
81
74http://clinicaltrials.gov/ct2/show/NCT01468909Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerA Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CarcinomaThis randomized phase II trial is studying how well giving paclitaxel with or without pazopanib hydrochloride works in treating patients with persistent or recurrent ovarian epithelial, fallopian tube, or peritoneal cavity cancer.http://clinicaltrials.gov/ct2/show/NCT01468909 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
82
75http://clinicaltrials.gov/ct2/show/NCT01294293VTX-2337 and Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerA Phase I Study of VTX-2337 (IND #78,416) in Combination With Doxil® (NSC# 712227) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerThis phase I trial is studying the side effects and best dose of VTX-2337 and liposomal doxorubicin hydrochloride in treating patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer.http://clinicaltrials.gov/ct2/show/NCT01294293 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
83
76http://clinicaltrials.gov/ct2/show/NCT01305213Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerA Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CarcinomaThis randomized phase II trial is studying how well giving bevacizumab with or without fosbretabulin tromethamine works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer.http://clinicaltrials.gov/ct2/show/NCT01305213 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
84
77http://clinicaltrials.gov/ct2/show/NCT01199263Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerA Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) Versus Weekly Paclitaxel With Oncolytic Reovirus (Reolysin® NSC # 729968, BB-IND # 13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal CancerThis randomized phase II trial is studying the side effects and how well giving paclitaxel with or without viral therapy works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01199263 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
85
78http://clinicaltrials.gov/ct2/show/NCT00445887Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian CancerPhase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND# 79,610)This randomized phase II trial is studying how well levonorgestrel works in preventing ovarian cancer in patients at high risk for ovarian cancer.http://clinicaltrials.gov/ct2/show/NCT00445887 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
86
79http://clinicaltrials.gov/ct2/show/NCT01465750Epidemiology of Ovarian Cancer in TaiwanEpidemiology of Ovarian Cancer in TaiwanCancer is the leading cause of mortality in the investigators country. According to the statistics of the Department of Health, the incidence of ovarian cancer increased in recent years and the mortality rate is highest in all gynecologic malignancies in Taiwan. Ovarian cancer becomes a more and more important disease gradually in the field of gynecologic malignancies. The classification of histology in ovarian cancer included epithelial ovarian cancer、germ cell tumors、sex-cord cell tumors…etc. Epithelial ovarian carcinoma is the most common ovarian cancer clinically. Early diagnosis is difficult due to the lack of obvious initial symptoms, so ovarian cancer patients are usually at advanced stage when the diagnosis is confirmed. The prognostic parameters for ovarian carcinomas include tumor stage, histological subtype, degree of malignancy, residual tumor after surgical intervention and the response to chemotherapy. However, the possible etiology and mechanism of ovarian cancer is still unclear. However, there is no epidemiologic data of ovarian cancer in Taiwan. Therefore the investigators propose this study to use Taiwan registry database provided by Department of Health to analyze the epidemiology and prognosis of ovarian cancer patients in Taiwan.http://clinicaltrials.gov/ct2/show/NCT01465750 - Retrieved June 2012National Taiwan University HospitalCurrently recruiting
87
80http://clinicaltrials.gov/ct2/show/NCT00005095Screening Methods for Finding Ovarian CancerNorthwestern Ovarian Cancer Early Detection & Prevention ProgramThis clinical trial is studying screening methods for identifying women who are at increased risk for developing ovarian cancer.http://clinicaltrials.gov/ct2/show/NCT00005095 - Retrieved June 2012Northwestern UniversityNational Cancer Institute (NCI)Currently recruiting
88
81http://clinicaltrials.gov/ct2/show/NCT00626873Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the OvaryMicrovascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian CancerThis clinical trial is studying how well contrast-enhanced ultrasonography works in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary.http://clinicaltrials.gov/ct2/show/NCT00626873 - Retrieved June 2012Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Currently recruiting
89
82http://clinicaltrials.gov/ct2/show/NCT01445275Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199A Comparative Effectiveness Study of Cancer Risk Management for Women at Elevated Genetic Risk of Ovarian CancerThis clinical trial is collecting information about types of treatment and the cost of these procedures.http://clinicaltrials.gov/ct2/show/NCT01445275 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruiting
90
83http://clinicaltrials.gov/ct2/show/NCT01216813Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological CancerThe Rehabilitation Needs of People Who Have Had an Upper Gastrointestinal or a Gynecological CancerThis clinical trial is studying the physical and psychosocial rehabilitation needs of patients after diagnosis and treatment of upper gastrointestinal cancer or gynecological cancerhttp://clinicaltrials.gov/ct2/show/NCT01216813 - Retrieved June 2012Royal Marsden NHS Foundation TrustCurrently recruiting
91
84http://clinicaltrials.gov/ct2/show/NCT01170299Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal CancerA Randomized Controlled Trial to Investigate the Role of Low or High 'Fibre' Diets in Patients Undergoing Pelvic Radiotherapy - The Fibre StudyThis randomized clinical trial is studying a high-fiber diet to see how well it works compared with a low-fiber diet in preventing bowel side effects in patients undergoing radiation therapy for gynecological cancer, bladder cancer, colorectal cancer, or anal cancer.http://clinicaltrials.gov/ct2/show/NCT01170299 - Retrieved June 2012Royal Masonic HospitalCurrently recruiting
92
85http://clinicaltrials.gov/ct2/show/NCT01540565Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerA Phase II Evaluation of the Potent, Highly Selective Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888) (IND #77840) (NSC #737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 MutationThis phase II trial studies how well veliparib works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT01540565 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
93
86http://clinicaltrials.gov/ct2/show/NCT01200797SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or CarboplatinA Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaThis phase II trial is studying how well SJG-126 works in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that did not respond to previous treatment with cisplatin or carboplatin.http://clinicaltrials.gov/ct2/show/NCT01200797 - Retrieved June 2012H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)Currently recruiting
94
87http://clinicaltrials.gov/ct2/show/NCT01459380Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerA Phase I Trial of Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube CancerThis randomized phase I trial studies the side effects and the best dose of veliparib given together with pegylated liposomal doxorubicin hydrochloride and carboplatin in treating patients with recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.http://clinicaltrials.gov/ct2/show/NCT01459380 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
95
88http://clinicaltrials.gov/ct2/show/NCT00958698Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNURSE-DELIVERED WRITE SYMPTOMS© vs. SELF-DIRECTED WRITE SYMPTOMS© vs. CARE AS USUAL FOR OPTIMAL SYMPTOM MANAGEMENT FOR WOMEN WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCERThis randomized clinical trial is studying two different symptom management programs to see how well they work compared with usual care in patients with recurrent or persistent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.http://clinicaltrials.gov/ct2/show/NCT00958698 - Retrieved June 2012Gynecologic Oncology GroupNational Cancer Institute (NCI)Currently recruiting
96
89http://clinicaltrials.gov/ct2/show/NCT00813423Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to ChemotherapyAutophagic Modulation With Anti-Angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and HydroxychloroquineThis phase I trial is studying the side effects and best dose of sunitinib when given together with hydroxychloroquine in treating patients with advanced solid tumors that have not responded to chemotherapy.http://clinicaltrials.gov/ct2/show/NCT00813423 - Retrieved June 2012University of Medicine and Dentistry New JerseyNational Cancer Institute (NCI)Currently recruiting
97
90http://clinicaltrials.gov/ct2/show/NCT01295632Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced CancerThis is a two part study of the drug MK-8669 (ridaforolimus) given with MK-2206 or MK-0752. In Part A of the study, the preliminary maximum tolerated dose (MTD) of the drug combinations will be found by giving sequentially higher doses of the study drugs. An expansion cohort of participants may be enrolled to confirm the MTD. New cohorts at other dose levels may be enrolled, depending on the rate of dose limiting toxicities (DLTs) in the planned cohorts. In Part B, an assessment of the efficacy of the drug combinations against selected advanced cancers will be made so that a recommended dose to be used in Phase 2 studies (RPTD) can be found.http://clinicaltrials.gov/ct2/show/NCT01295632 - Retrieved June 2012MervkCurrently recruiting
98
91http://clinicaltrials.gov/ct2/show/NCT00976183Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian CarcinomaA Phase I/II, Open-Label, Non-Randomized, Pilot Study of Weekly Paclitaxel, Every Four-week Carboplatin and Oral Vorinostat for Patients Newly Diagnosed With Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal CancerSince the mortality rates for patients with advanced ovarian carinoma are high, the most likely way to improve progression free and overall survival is with maximal "upfront" therapy (Morrow & Curtin, 1998). Currently, no triplet regimen has demonstrated compelling superiority. Therefore, the combination of Paclitaxel, Carboplatin, and Vorinostat is intriguing because of their potential synergy, distinct mechanisms of action, and non-overlapping toxicity.http://clinicaltrials.gov/ct2/show/NCT00976183 - Retrieved June 2012Gynecologic Oncology AssociatesMerckCurrently recruiting
99
92http://clinicaltrials.gov/ct2/show/NCT01199796Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial OvarianA Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaThe purpose of this study is to see if the experimental drug SJG-136 is effective in treating this type of cancer and to find out the types and severity of side effects caused by treatment with this study drug.http://clinicaltrials.gov/ct2/show/NCT01199796 - Retrieved June 2012H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)Currently recruiting
100
93http://clinicaltrials.gov/ct2/show/NCT01097746First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian CancerA Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube CarcinomaThe goal of this clinical research study is to learn if therapy with bevacizumab, carboplatin, and weekly doses of paclitaxel is safe and can be tolerated in patients with newly diagnosed epithelial ovarian, primary peritoneal, or fallopian tube cancer. Researchers will also study if and how well this study therapy may help to control the disease.http://clinicaltrials.gov/ct2/show/NCT01097746 - Retrieved June 2012M.D. Anderson Cancer CenterGenentechCurrently recruiting